A Study to Evaluate the Safety and Efficacy of MGD013 in Patients With Melanoma

Stopped rapid changes in the treatment mode of melanoma worldwide and in China and the development strategy change

Conditions

• Unresectable, Recurrent or Metastatic Melanoma
• Untreated Mucosal or Acral Lentiginous Melanoma

Interventions

• DRUG: MGD013

Sponsor

Zai Lab (Shanghai) Co., Ltd.